Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study.

Cancer Immunol Immunother · 2024 · PMC11162406 · PMID 38850359

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

In subgroups ESCC, GC, MSI-H CRC, HCC, BTC, NSCLC and HNSCC, CCS/CRF group patients showed better therapeutic effects in both ORR and DCR, although it did not reach statistical significance (all P > 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.